Janone wins "best abstract" award at the ohio society of interventional pain physicians annual meeting

Abstract explained jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior phase ii study. las vegas , aug. 25, 2023 /prnewswire/ -- janone (nasdaq: jan), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "best abstract" award for reporting that janone's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function.
JAN Ratings Summary
JAN Quant Ranking